Does Keynote 189 establish combination chemoimmunotherapy as the standard of care for Stage IV lung adenocarcinoma?
Given the prior results of Keynote 189, how do you plan to utilize the data from Keynote 042 with pembrolizumab monotherapy?
Community PollStarted
What is your first line treatment for nonmutated metastatic lung adenocarcinoma in light of Keynote 189 and 042?
90 physicians have voted
Join Mednetto vote and see how they answered.
1 Answer
Mednet MemberInvited Expert
Medical Oncology · UCSD Moores Cancer Center
Answered on
If the Insigna trial is available, to me that is the best way of addressing this. Otherwise I would not. To me KN189/407 represents the current standard of care in the US relative to KN42 which appears inferior. For those that make argument about patient with poor performance status etc for KN42, th...
Join for free or sign in to see the full answer